Member Info for HotblackDesiato

Morning SOG - I did wonder that too as to who has those 9m shares. If any individual or company holds them they'd have to issue a TR1 so I can only assume they've been sold on to entities holding less than 3% of the company. Unless as the broker, Hydridan are exempt from that rule and can drip-feed them as required. I'd presume they stumped up the £955k and paid SAR meaning Hydridan could then profit from the sale into the market - perks of being a broker, I suppose.

At least PH didn't benefit as far as we know.

Hi Krone/SOG - interesting stuff (well, maybe only to some of us). I've looked at the data in Table 18 available in the supplementary section of the report and 737 appears to have been researched by AstraZeneca in combo with either Gemcitabine, 5-Fluorouracil, AZD1775 or SN-38 for the following list of cancers -

B-Lymphoblastic Leukemia

Melanoma

B-Cell Non-Hodgkin's Lymphoma

Non-Cancerous

Pancreatic Carcinoma

Head and Neck Carcinoma

Neuroblastoma

Breast Carcinoma

Burkitt's Lymphoma

Glioblastoma

Small Cell Lung Carcinoma

Esophageal Squamous Cell Carcinoma

Esophageal Adenocarcinoma

Mesothelioma

Oral Cavity Carcinoma

Osteosarcoma

Gastric Carcinoma

Ovarian Carcinoma

Lung Adenocarcinoma

Ewing's Sarcoma

Colorectal Carcinoma

Kidney Carcinoma

Thyroid Gland Carcinoma

T-Lymphoblastic Leukemia

Chondrosarcoma

Plasma Cell Myeloma

T-Cell Non-Hodgkin's Lymphoma

Cervical Carcinoma

Hepatocellular Carcinoma

Bladder Carcinoma

Other Solid Carcinomas

Endometrial Carcinoma

Acute Myeloid Leukemia

Non-Small Cell Lung Carcinoma

Squamous Cell Lung Carcinoma

Chronic Myelogenous Leukemia

Other Blood Carcinomas

Rhabdomyosarcoma

Prostate Carcinoma

Low Grade Glioma

Hodgkin's Lymphoma

Biliary Tract Carcinoma

AstraZeneca wouldn't be putting so much effort into research with 737 if they didn't think it had potential.

Regards.

Preyno - You seem to have interpreted my post incorrectly to imply the BoD would give away insider information for another's financial gain (the FCA might have an opinion if that happened) and also assumed that individual would repeat such info on a public forum.

Direct access could simply be used to put across widespread concerns such as, are PH really the right people for the job? Such access would ensure shareholders didn't have to rely on either the BoD seeing their comment here or playing e-mail roulette with the investor relations contact.

It could also explain why the 1802 translational studies are taking so long (ignoring the funding issues).

Thanks Aber for the considered response. The closest we may come to having an individual on hand to keep the BoD honest is if any of our HNW chums are able to pick up the phone and contact Tim directly. Surely injecting such large amounts into SAR's coffers buys you some perks such as direct access to the BoD even if they can't tell you anything market sensitive.

Regards.

My thoughts too, Potnak. Far to difficult to appoint someone, even one of the HNWs would probably shy away from the required scrutiny from us lot.

If Parker gets a hard time on here from LTHs, imagine what an (un)elected punter would get.

Hi Aber - so what would be the vetting process for this nominated shareholder? How would we trust them with insider knowledge etc.? It's fine if they have a sufficient number of shares (is it 5% or 10% you need to get a seat on the board?) but otherwise what criteria would they need to have - a business degree? Otherwise they may be more of a hindrance than a help.

Hi Basil - it'd be interesting to know how many drugs developed by large pharma are able to skip P1b, not too many I suspect. I hope news of our intent is spreading through the pharma grapevine and we attract a major as a partner. That would put us firmly on the radar when it comes to 1802.

Morning Bobbler - I had looked at Boehringer Ingelheim before but wrote them off as they're wholly privately owned so I presumed there would be no shares available to offer i.e. with a revenue of $9bn and no shares in circulation as such, how do we value circa 136000 shares in the company?

That all said, I'm puzzled by the following link - https://annualreport.boehringer-ingelheim.com/2023/letter/shareholder/index.html

If anyone can read or access it, good luck.

Regards.

Morning Celtic - that's just how business works sometimes. We just have to wait and see.

Hi Lsesar - having completed P2 trials in combo, the BoD may have presumed 737 was at a point in its development that would attract larger upfront payments upon further licensing. Seems perfectly reasonable to me based on what I've read regarding deals for potentially P3-ready compounds. So who here expected a near carbon-copy of the Sierra deal?

Celtic - it's near enough 4mths since the license was announced and there isn't even a hint of who has it in any corner of the internet. For all we know it's been renamed and is currently undergoing preclinical research in combination with other drugs prior to trials in humans.

I keep looking on the US clinical trials website for any newly registered trials mentioning chk1 or anything that could be linked to 737 - nothing to report so far.

We can't even say for sure if our own BoD know who has it. You'd have thought the US firm would announce the deal in a 'look at us! see what we're doing now!' kind of way. I can only hope bigger games are being played behind the scenes and we'll all be pleasantly surprised when we know what's really going on.

Although Potnak suggests it might be with a small company looking to do a bit of work on it before selling it on (which is plausible), I'd be surprised if the CPF picked a small company over a larger pharma to progress 737 (assuming large pharma were interested).

In a nutshell, I'm stumped.

Conz/Dorset - at the time the BoD maybe knew a 737 license was in the closing stages and they probably thought there'd be an upfront payment large enough to cover our needs so RF was just a 'short-term payday loan' that turned out to be ill-advised and/or poorly chosen. Suddenly it went from we only need a a few quid to tide us over until the end of the month to oh crikey, we're now tied to a chair in a deserted warehouse and our kneecaps are soon to be history.

Luckily, enough shareholders heard the screaming and burst in to save the day.

Hi Celtic - any intellectual property Sierra was able to develop whilst 737 was licensed to them should be handed over to the CRT Pioneer Fund as they are the owners of 737 (we are only financial beneficiaries if there's a commercial license). This doesn't stop anyone from patenting a novel use of the compound e.g. the Celtic007 Pharmaceuticals & Dangerous Toy Company Ltd doesn't own the rights to 737 but you could patent a use which if approved means someone would have to pay you a fee if their use infringes your patent.

If you look at another patent (see below) and click on the 'show all events' filter in the right-hand column, you'll see an entry dated 5/2/24 that says the patent is assigned to CRT Pioneer Fund.

https://patents.google.com/patent/US20210077499A1/en?oq=US20210077499A1

It's possible all IP has been handed over by Sierra but the admin side is yet to filter through to all the patents. I still think our mystery licensee is Sierra (again) as they have so much work in the compound & patents.

Looks like Sierra are keeping a tight grip on patents covering 737. The link below shows a Japanese application was published on 30/1/24 so they're obviously happy to keep paying for the patent process though not sure if it's now effectively assigned to CPF.

https://patentscope.wipo.int/search/en/result.jsf?_vid=P22-LVMG62-27469

Boyasaka - the BoD already has enough info for them to announce they are looking to start P2a trials this year but you ask what if the data isn't positive? Without positive data the BoD will have announced their own demise which would be an odd thing to do.

Yet by skipping P1b, the net result must be we've brought P2a forward. Mind you, time is an illusion so.....

Hi Potnak - with P2a likely to start this year, 2026 might be quite pessimistic for getting the data readout on 24 patients but who knows?

One big thing that will play into our hands is the fact we're skipping P1b. This seems to be a rare event in the pharma world and it'll get the attention of many interested parties therefore I don't see us going it alone. Yes, a partner will want a percentage ownership of 1801 (or whatever) but if it adds value and means no dilution then many will be able to live with that outcome. I just hope any deal isn't as opaque as the 737 one!

As for buys drying up, I guess that's maybe to be expected. Those of us who had funds at the start of the month will have bought asap and now I think potential new investors are holding off until P1a results are announced. Positive results will greatly derisk things and will point to the BoD's next intentions. If we partner with a major pharma for P2a then they may also be interested in 1802 and therefore by default, the whole company.

Hi Potnak - They stated that if they used the full £5m from RF plus £1.6m tax credits then that'd see P1b covered plus spare cash 'til the end of 2024. The original plans for P1b required 24 volunteers and it's still 24 for P2a so how do you arrive at us now needing £10m?

Hi Blue - not to take anything away from SAR and the SKIL platform, kinase inhibitor libraries are fairly common and I'd imagine all the large pharmas will have their own. I guess the value is in how you utilise it.